BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6095753)

  • 1. Correlation of the effect of beta-lactamase inhibitors on the beta-lactamase in growing cultures of gram-negative bacteria with their effect on the isolated beta-lactamase.
    Easton CJ; Knowles JR
    Antimicrob Agents Chemother; 1984 Sep; 26(3):358-63. PubMed ID: 6095753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
    Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S
    Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of five irreversible inhibitors on beta-lactamase from Shigella flexneri UCSF-129.
    Campos M; Alarcón MA; González H; Sánchez R
    Microbios; 1993; 76(308):171-9. PubMed ID: 8302198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of aminopenicillins combined with sulbactam, clavulanic acid, or amdinocillin against bacteria isolated from patients with complicated urinary tract infections.
    Naber KG; Wittenberger R
    Rev Infect Dis; 1986; 8 Suppl 5():S604-8. PubMed ID: 3026011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
    Aronoff SC; Jacobs MR; Johenning S; Yamabe S
    Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefoxitin, N-formimidoyl thienamycin, clavulanic acid, and penicillanic acid sulfone as suicide inhibitors for different types of beta-lactamases produced by gram-negative bacteria.
    Sawai T; Tsukamoto K
    J Antibiot (Tokyo); 1982 Nov; 35(11):1594-602. PubMed ID: 6298169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of beta-lactamase inhibitors in chemotherapy.
    Neu HC
    Pharmacol Ther; 1985; 30(1):1-18. PubMed ID: 3018803
    [No Abstract]   [Full Text] [Related]  

  • 14. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.
    Neu HC
    Antimicrob Agents Chemother; 1982 Sep; 22(3):518-9. PubMed ID: 6291454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX; McElrath MJ; Neu HC
    Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
    Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
    Grace ME; Fu KP; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.
    Moosdeen F; Williams JD; Yamabe S
    Antimicrob Agents Chemother; 1988 Jun; 32(6):925-7. PubMed ID: 2843088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.
    Moosdeen F; Keeble J; Williams JD
    Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.